Systemic treatment of vitreous inflammation

John B Christoforidis, Susie Chang, Angela Jiang, Jillian Wang, Colleen M. Cebulla

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Non infectious vitreous inflammation is often vision threatening and can be associated with potentially life-threatening systemic conditions. Treatment is often challenging as it involves systemic medications that can be associated with adverse effects. The classes of drugs are ever expanding and include corticosteroids, antimetabolites, alkylating agents, T-cell and calcineurin agents, biologic agents, and interferons. Each class of systemic therapy for non-infectious vitreous inflammation is reviewed. We discuss the mechanisms of action, usual clinical dosages, the specific conditions that are treated, the adverse effects, and usual course of treatment for each class of therapy.

Original languageEnglish (US)
Article number936721
JournalMediators of Inflammation
Volume2012
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Inflammation
Antimetabolites
Calcineurin
Alkylating Agents
Biological Factors
Therapeutics
Interferons
Adrenal Cortex Hormones
T-Lymphocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Systemic treatment of vitreous inflammation. / Christoforidis, John B; Chang, Susie; Jiang, Angela; Wang, Jillian; Cebulla, Colleen M.

In: Mediators of Inflammation, Vol. 2012, 936721, 2012.

Research output: Contribution to journalArticle

Christoforidis, John B ; Chang, Susie ; Jiang, Angela ; Wang, Jillian ; Cebulla, Colleen M. / Systemic treatment of vitreous inflammation. In: Mediators of Inflammation. 2012 ; Vol. 2012.
@article{6289c386ae71477cb8b130a52222dd8e,
title = "Systemic treatment of vitreous inflammation",
abstract = "Non infectious vitreous inflammation is often vision threatening and can be associated with potentially life-threatening systemic conditions. Treatment is often challenging as it involves systemic medications that can be associated with adverse effects. The classes of drugs are ever expanding and include corticosteroids, antimetabolites, alkylating agents, T-cell and calcineurin agents, biologic agents, and interferons. Each class of systemic therapy for non-infectious vitreous inflammation is reviewed. We discuss the mechanisms of action, usual clinical dosages, the specific conditions that are treated, the adverse effects, and usual course of treatment for each class of therapy.",
author = "Christoforidis, {John B} and Susie Chang and Angela Jiang and Jillian Wang and Cebulla, {Colleen M.}",
year = "2012",
doi = "10.1155/2012/936721",
language = "English (US)",
volume = "2012",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Systemic treatment of vitreous inflammation

AU - Christoforidis, John B

AU - Chang, Susie

AU - Jiang, Angela

AU - Wang, Jillian

AU - Cebulla, Colleen M.

PY - 2012

Y1 - 2012

N2 - Non infectious vitreous inflammation is often vision threatening and can be associated with potentially life-threatening systemic conditions. Treatment is often challenging as it involves systemic medications that can be associated with adverse effects. The classes of drugs are ever expanding and include corticosteroids, antimetabolites, alkylating agents, T-cell and calcineurin agents, biologic agents, and interferons. Each class of systemic therapy for non-infectious vitreous inflammation is reviewed. We discuss the mechanisms of action, usual clinical dosages, the specific conditions that are treated, the adverse effects, and usual course of treatment for each class of therapy.

AB - Non infectious vitreous inflammation is often vision threatening and can be associated with potentially life-threatening systemic conditions. Treatment is often challenging as it involves systemic medications that can be associated with adverse effects. The classes of drugs are ever expanding and include corticosteroids, antimetabolites, alkylating agents, T-cell and calcineurin agents, biologic agents, and interferons. Each class of systemic therapy for non-infectious vitreous inflammation is reviewed. We discuss the mechanisms of action, usual clinical dosages, the specific conditions that are treated, the adverse effects, and usual course of treatment for each class of therapy.

UR - http://www.scopus.com/inward/record.url?scp=84867818487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867818487&partnerID=8YFLogxK

U2 - 10.1155/2012/936721

DO - 10.1155/2012/936721

M3 - Article

C2 - 23028205

AN - SCOPUS:84867818487

VL - 2012

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 936721

ER -